Valeria Santini, MD, discusses advances in the treatment of myelodysplastic syndromes, including new therapeutic options for patients with lower-risk disease.
“We do not only want to improve the quality of life, but also prolong survival,” Dr. Santini said.
In addition to discussing the shift toward earlier intervention in patients with anemia, she discussed the role of luspatercept and imetelstat in treatment, and emerging strategies to reduce transfusion dependence.
Dr. Santini also examines how advances in treatment may improve long-term outcomes and reshape expectations for patients.
Leave feedback about this